May 04, 2020 Rett failure sets up thin pipeline Newron’s failure in Rett syndrome leaves the late-stage pipeline to GW Pharma, Acadia and Anavex.
February 24, 2020 First fragile X test is approved, and Zynerba could benefit The fragile X pipeline is strewn with failures, and crunch time is approaching for Zynerba’s cannabinoid.
September 06, 2019 Upcoming events – Obseva's first fibroid foray and Newron's test in Retts Obseva awaits data that could make linzagolix third to market, while Newron looks for a starring role in Retts.
August 07, 2018 Neuren pays the price for sellside froth The Australian group has found a partner for its lead asset at last, so why is the stock down?